0.3239
price up icon6.20%   0.0189
pre-market  시장 영업 전:  .34   0.0161   +4.97%
loading

Adaptimmune Therapeutics Plc Adr 주식(ADAP)의 최신 뉴스

pulisher
Apr 02, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com

Apr 02, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India

Apr 01, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

Adaptimmune Therapeutics Amends Loan Agreement - Investing.com India

Mar 24, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com

Mar 21, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com

Mar 20, 2025
pulisher
Mar 06, 2025

Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Feb 25, 2025

LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025
pulisher
Feb 25, 2025

Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register

Feb 25, 2025
pulisher
Feb 19, 2025

Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily

Feb 19, 2025
pulisher
Feb 12, 2025

Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex

Feb 11, 2025
pulisher
Feb 08, 2025

Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

SM Energy Co (SM): A Technical Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 04, 2025

Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex

Feb 04, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 16, 2025

Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India

Jan 16, 2025
pulisher
Jan 15, 2025

Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com

Jan 15, 2025
pulisher
Jan 15, 2025

Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com

Jan 15, 2025
pulisher
Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024
pulisher
Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024
pulisher
Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024
pulisher
Dec 02, 2024

Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail

Dec 02, 2024
pulisher
Nov 27, 2024

Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com

Nov 27, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024
pulisher
Nov 18, 2024

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

Nov 18, 2024
pulisher
Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024
pulisher
Nov 05, 2024

ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Adaptimmune faces Nasdaq delisting over share price - Investing.com India

Nov 01, 2024
pulisher
Oct 22, 2024

Validea Kenneth Fisher Strategy Daily Upgrade Report10/22/2024 - Nasdaq

Oct 22, 2024
pulisher
Oct 17, 2024

NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register

Oct 17, 2024
pulisher
Oct 16, 2024

Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024
pulisher
Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):